Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Saskatchewan adopts biosimilar switching program for 6th province/territory

by | Oct 20, 2022

The Saskatchewan Ministry of Health announced the introduction of a biosimilar switching program – the 6th of its kind to be introduced into provinces/territories in Canada. Under the new program, the Saskatchewan Drug Plan will only cover listed biosimilars for new patients starting on biologic drugs.  The program will initially include 10 medications, with new biosimilars to be added as they become available.  Existing patients are expected to transition to biosimilars by 30 April 2023.  The Ministry of Health reported that it expects the program to result in annual savings of $20 million once the transition is complete.  Saskatchewan is the fifth Canadian province to adopt a biosimilars switching program, following similar moves by British Columbia, New Brunswick, Quebec and Nova Scotia.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News